Darunavir / cobicistat

Phenytoin

Contraindicated.

No pharmaceutical opinion available for this interaction.

Mechanism

Phenytoin can induce the metabolism (CYP 3A4) and decrease the plasma concentration of Darunavir / cobicistat.

Darunavir / cobicistat

Pharmacodynamic effects

Possible decrease of clinical efficacy.

Risk of a possible development of resistance to antiretroviral class.

Recommendations

Avoid this association or monitor for signs and symptoms of therapeutic failure.

Alternative solution(s)

Phenytoin

Pharmacodynamic effects

Recommendations

Contraindicated. Use alternative.

Alternative solution(s)

As clinically indicated : brivaracetam, gabapentin, lacosamide, lamotrigine, levetiracetam, pregabalin, rufinamide, topiramate, vigabatrin, zonisamide.

Monitor

Tests

Darunavir plasma level

CD4+

Viral Load

Pharmacokinetic parameters

Comment

Reference
  • 3071
    Darunavir/cobicistat (Prezcobix), Janssen, Ontario, Canada, 7 avril 2017.
  • 3142
    Phenytoine (Dilantin), Pfizer, Québec, Canada, 22 juil 2013.
  • 3437
    Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza), Janssen Inc, Ontario, Canada, 3 octobre 2018.